Equillium Inc.

Address: 2223 Avenida De La Playa Suite 108

Sponsor Overview

assignment

Specializations

Acute Graft Versus Host Disease

Clinical research is focused on acute graft-versus-host disease, a serious immune complication that can occur after bone marrow transplantation or hematopoietic stem cell transplantation. The trial activity centers on initial treatment strategies for controlling early inflammatory disease expression.

Immune-mediated transplant complications
Allogeneic stem cell transplantation
Corticosteroid-based therapy

Research interest in this area reflects a therapeutic focus on improving management of transplant-related graft-versus-host disease through targeted immunomodulatory approaches.

Inflammatory and Immune Regulation

The sponsor’s clinical activity addresses immune dysregulation and inflammatory pathways involved in transplant-associated tissue injury. This includes interest in therapies aimed at reducing pathological immune activation while preserving transplant outcomes.

Immune suppression
Inflammation control
Transplant immunology

The therapeutic domain is centered on conditions where excessive immune responses drive organ and tissue damage after transplantation.

Combination Treatment Approaches

Research interest includes combination therapy in which an immunomodulatory agent is used together with corticosteroids for early disease control. The clinical focus is on improving response in patients with newly diagnosed acute graft-versus-host disease.

First-line treatment
Early disease response
Supportive transplant care

This area highlights interest in treatment strategies designed for prompt control of immune complications following transplantation.

Targeted Immunotherapy

The sponsor is involved in research on targeted immunotherapy for transplant complications, with attention to biologic approaches that modulate specific immune pathways. The therapeutic emphasis is on disease control in allogeneic transplant recipients.

Biologic immunomodulation
Transplant recipient care
Immune pathway targeting

Clinical interest remains concentrated on therapies for immune-mediated conditions arising in the post-transplant setting.

Trial Name	Country	Status
Evaluation of Itolizumab and Corticosteroids for Initial Management of Acute Graft Versus Host Disease in a Phase 3 Randomized Controlled Trial	Belgium France Germany Italy Portugal Spain	Not Recruiting